Why Summit Therapeutics Skyrocketed 123% This Week
The Motley FoolBetter-than-expected trial data means Summit’s bispecific antibody could replace the blockbuster Keytruda as a standard of care for certain lung cancers.
Better-than-expected trial data means Summit’s bispecific antibody could replace the blockbuster Keytruda as a standard of care for certain lung cancers.